Martin Hoenigl, Amir Arastehfar, Maiken Cavling Arendrup, Roger Brüggemann, Agostinho Carvalho, Tom Chiller, Sharon Chen, Matthias Egger, Simon Feys, Jean-Pierre Gangneux, Jeremy A W Gold, Andreas H Groll, Jannes Heylen, Jeffrey D Jenks, Robert Krause, Katrien Lagrou, Frédéric Lamoth, Juergen Prattes, Sarah Sedik, Joost Wauters, Nathan P Wiederhold, George R Thompson
SUMMARYFungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, and their utility and efficacy in antifungal treatment are limited by one or more of innate or acquired resistance in some fungi, poor penetration into "sequestered" sites, and agent-specific side effect which require frequent patient reassessment and monitoring. Agents with novel mechanisms, favorable pharmacokinetic (PK) profiles including good oral bioavailability, and fungicidal mechanism(s) are urgently needed...
April 11, 2024: Clinical Microbiology Reviews